Regulatory Filings • Nov 15, 2022
Regulatory Filings
Open in ViewerOpens in native device viewer
Receipt of the decision on granting patent protection for the inventionin the territory of Brazil.
TheExecutive Board of Genomtec S.A. ("Company", "Issuer") registered inWroclaw, Poland, hereby reports that today The Company has learned abouta positive decision of the Brazilian Patent Office granting the Companypatent protection for an invention entitled _quot;A method of detectinggenetic material in a biological sample and a device for itsimplementation_quot;._#160;
Theinvention covers the key technical solutions related to the proprietarycontactless heating and temperature detection system developed for POCTplatforms, including Genomtec ID.TheIssuer informs that this is the first patent granted by the BrazilianPatent Office and the eighth patent received by the Company. The Issueris pending over twenty five patent applications all over the world.
TheIssuer's Management Board decided that the receipt of the above patentis confidential information, as in the case of an entity operating onthe molecular diagnostics market, it is necessary to effectively protectintellectual and industrial property. Properly secured intellectual andindustrial property may constitute the Issuer's competitive advantage -and its safe commercialization is possible provided that full protectionis ensured on selected markets.Inthe opinion of the Management Board, a high level of intellectualproperty protection will also provide the Company with an appropriatenegotiating position before signing commercial agreements with selectedpartners in the scope of implementing the commercialization strategy.
Patentproceedings are aimed at securing key interests and are in line with theIssuer's development strategy, which includes building a portfolio ofintellectual property rights. POCT diagnostics using the Genomtec IDplatform is the key area of the Issuer's operations. For these reasons,in the opinion of the Management Board, this information meets thecriteria of confidential information within the meaning of Art. 7 sec. 1MAR.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.